BeOne Medicines annual asset turnover
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeOne Medicines Asset Turnover Growth & History (ONC)
BeOne Medicines's asset turnover was 0.76 for fiscal 2025.
View full BeOne Medicines company overviewBeOne Medicines annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.76 | 0.11 | +16.54% |
| 2024 | 2024-12-31 | 0.65 | 0.25 | +61.02% |
| 2023 | 2023-12-31 | 0.40 | 0.21 | +112.56% |
| 2022 | 2022-12-31 | 0.19 | 0.02 | +14.09% |
| 2021 | 2021-12-31 | 0.17 | 0.08 | +94.32% |
| 2020 | 2020-12-31 | 0.09 | −0.14 | −61.38% |
| 2019 | 2019-12-31 | 0.22 | 0.10 | +84.38% |
| 2018 | 2018-12-31 | 0.12 | −0.21 | −63.36% |
| 2017 | 2017-12-31 | 0.33 | 0.32 | +7916.69% |
| 2016 | 2016-12-31 | 0.00 | — | — |
BeOne Medicines quarterly asset turnover
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Asset turnover | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.79 | 0.03 | +4.28% |
| Q1 2026 | 2026-03-31 | 0.80 | 0.07 | +9.88% |
| Q4 2025 | 2025-12-31 | 0.76 | 0.11 | +16.54% |
| Q3 2025 | 2025-09-30 | 0.74 | 0.15 | +26.45% |
| Q2 2025 | 2025-06-30 | 0.76 | 0.22 | +40.34% |
| Q1 2025 | 2025-03-31 | 0.73 | 0.25 | +52.67% |
| Q4 2024 | 2024-12-31 | 0.65 | 0.25 | +61.02% |
| Q3 2024 | 2024-09-30 | 0.58 | 0.22 | +62.32% |
| Q2 2024 | 2024-06-30 | 0.54 | 0.26 | +95.91% |
| Q1 2024 | 2024-03-31 | 0.48 | 0.25 | +113.35% |
| Q4 2023 | 2023-12-31 | 0.40 | 0.21 | +112.56% |
| Q3 2023 | 2023-09-30 | 0.36 | 0.15 | +72.95% |
| Q2 2023 | 2023-06-30 | 0.28 | 0.11 | +66.81% |
| Q1 2023 | 2023-03-31 | 0.22 | 0.10 | +75.82% |
| Q4 2022 | 2022-12-31 | 0.19 | 0.02 | +14.09% |
| Q3 2022 | 2022-09-30 | 0.21 | 0.01 | +6.28% |
| Q2 2022 | 2022-06-30 | 0.17 | −0.04 | −17.55% |
| Q1 2022 | 2022-03-31 | 0.13 | −0.05 | −27.38% |
| Q4 2021 | 2021-12-31 | 0.17 | 0.08 | +94.32% |
| Q3 2021 | 2021-09-30 | 0.20 | 0.12 | +174.42% |
| Q2 2021 | 2021-06-30 | 0.20 | 0.13 | +170.61% |
| Q1 2021 | 2021-03-31 | 0.17 | 0.05 | +35.26% |
| Q4 2020 | 2020-12-31 | 0.09 | −0.14 | −61.38% |
| Q3 2020 | 2020-09-30 | 0.07 | −0.13 | −64.41% |
| Q2 2020 | 2020-06-30 | 0.07 | −0.15 | −67.46% |
| Q1 2020 | 2020-03-31 | 0.13 | 0.00 | +2.80% |
| Q4 2019 | 2019-12-31 | 0.22 | 0.10 | +84.38% |
| Q3 2019 | 2019-09-30 | 0.20 | 0.11 | +119.75% |
| Q2 2019 | 2019-06-30 | 0.23 | −0.08 | −25.01% |
| Q1 2019 | 2019-03-31 | 0.13 | −0.13 | −51.70% |
| Q4 2018 | 2018-12-31 | 0.12 | −0.21 | −63.36% |
| Q3 2018 | 2018-09-30 | 0.09 | −0.25 | −73.39% |
| Q2 2018 | 2018-06-30 | 0.30 | 0.30 | — |
| Q1 2018 | 2018-03-31 | 0.26 | 0.26 | +21119.22% |
| Q4 2017 | 2017-12-31 | 0.33 | 0.32 | +7916.69% |
| Q3 2017 | 2017-09-30 | 0.34 | — | — |
| Q2 2017 | 2017-06-30 | 0.00 | — | — |
| Q1 2017 | 2017-03-31 | 0.00 | — | — |
| Q4 2016 | 2016-12-31 | 0.00 | — | — |
BeOne Medicines asset turnover trends
Over the last five fiscal years, BeOne Medicines's asset turnover increased from 0.09 to 0.76, a change of 0.67. The latest reported quarter, Q2 2026, shows 0.79.
About the metric
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
Calculation and source
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines source filings ↗Community posts
BeOne’s initial clinical results support planned late-stage studies
BeOne Medicines ($ONC) disclosed new dose-optimization findings for BGB-B2033 in heavily pretreated liver cancer. At the proposed Phase 3 dose, the bispecific antibody produced confirmed responses in 36% of patients, with an estimated 74.1% ...
